Seattle elects Nancy Simonian to board
This article was originally published in Scrip
Seattle Genetics, a biotech focused on the development of monoclonal antibodies to treat cancer, has appointed Dr Nancy Simonian to its board of directors. Dr Simonian most recently served as chief medical officer at Millennium: The Takeda Oncology Company, where she worked from 2001-2011. She is currently an independent consultant to the biotechnology industry.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.